AstraZeneca and Daiichi set to broaden use of breast cancer drug, challenging Roche
Bio Pharma Dive
MAY 5, 2022
The FDA cleared Enhertu for second-line use in HER2-positive disease, the latest inroads the partners have made against Roche’s dominant portfolio of breast cancer medicines.
Let's personalize your content